---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-005637"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:00:48.729484+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome

## Summary
- First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.
- MHRA authorized UK CTA for TSHA-102 in pediatric patients, expanding REVEAL into the UK.
- Initial safety and efficacy data for cohort one (low dose, n=3) expected in mid-2024.
- TSHA-102 uses miRARE technology to mediate MECP2 expression on a cell-by-cell basis.
- TSHA-102 also has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

## SEC filing metadata
- accession: 0001193125-24-005637
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/0001193125-24-005637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/d674544d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-005637
- JSON: https://secwatch.observer/filing/0001193125-24-005637.json
- Plain text: https://secwatch.observer/filing/0001193125-24-005637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.